Treatment Modification Common With Second-Line Antidiabetic Meds

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- Most patients with type 2 diabetes initiating antidiabetic medication (ADM) experience treatment modification within one year, according to a study published in the December issue of the American Journal of Managed Care.

David T. Liss, Ph.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues conducted a retrospective cohort study to describe changes in ADM use after initiation of noninsulin second-line therapy. Adults with type 2 diabetes who initiated one of five index ADM classes were analyzed; three treatment modification outcomes were assessed over 12-month follow-up.

The researchers found that 63.6 percent of the 82,624 included adults experienced any treatment modification. The most common modification was discontinuation (38.6 percent), especially among those prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 50.3 percent). Switching and intensification occurred in 5.2 and 19.8 percent of patients, respectively. In adjusted analyses, discontinuation risk was higher among patients prescribed dipeptidyl peptidase 4 inhibitors and GLP-1 RAs compared with those prescribed sulfonylureas (hazard ratios, 1.07 and 1.28, respectively). Higher risks of switching and lower risks of intensification were seen for all other index ADM classes compared with sulfonylureas. Higher risk of all modifications was seen in association with younger age group and female sex. Index prescription by an endocrinologist was associated with lower discontinuation risk and higher intensification risk compared with index prescription by a family medicine or internal medicine physician.

"Future research is needed to improve our understanding of barriers to ADM adherence among patients who discontinue second-line therapy," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-15 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords